Informing shareholders, the drug maker said its oncology segment suffered in the last financial year due to pricing controls from the government, and its Hepatitis-C business continued to decline due to reduction in market size.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/35TbyyL
via IFTTT
0 comments:
Post a Comment